Drug
Nemolizumab clinical trials
- studies test it
- 26
- open now
- 7
- in phase 3
- 10
- first study started
- 2013
Keep track of what changes. Save the nemolizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- CD14152
- 14
Brand
Studies by the year they started
26 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 14
- Phase 3
- 10
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 3
Galderma R&D (20) · Maruho Co., Ltd. (1) · Chugai Pharmaceutical (1) · Mayo Clinic (1) · University of Texas Southwestern Medical Center (1) · University of California, San Francisco (1) · The Skin Center Dermatology Group (1)
Often tested with
Tested in the same studies.
Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1) · Etanercept (1)
Studies
Open first, then newest update. How each study uses nemolizumab is read from its arms, and is right about nine times in ten.
Testing it · 26
- Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisRecruitingPhase 3Galderma R&DNCT07762833Written as Nemolizumab 30 mg
- Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic PruritusNot yet recruitingPhase 2Mayo ClinicNCT07843420Written as Nemolizumab-ilto
- Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic DermatitisRecruitingPhase 2Galderma R&DNCT07660835Written as Nemolizumab
- Nemolizumab for LSNot yet recruitingPhase 2University of Texas Southwestern Medical CenterNCT07704775Written as Nemolizumab 30 mg
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Nemolizumab
- A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisRecruitingPhase 2Galderma R&DNCT07047690Written as Nemolizumab
- Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.RecruitingPhase 4The Skin Center Dermatology GroupNCT07396168Written as Nemolizumab
- Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic DermatitisCompletedPhase 3Galderma R&DNCT03989206Written as Nemolizumab
- Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)Active, not recruitingPhase 2Galderma R&DNCT07074977Written as nemolizumab
- Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Galderma R&DNCT04921345Written as Nemolizumab
- A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With NemolizumabCompletedPhase 2Galderma R&DNCT04365387Written as Nemolizumab
- To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe PruritusCompletedPhase 2/3Galderma R&DNCT05075408Written as Nemolizumab
- An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic SclerosisCompletedPhase 2Maruho Co., Ltd.NCT05214794Written as nemolizumab
- A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Active, not recruitingPhase 3Galderma R&DNCT04204616Written as Nemolizumab
- Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber SyringeCompletedPhase 1Galderma R&DNCT05405985Written as Nemolizumab
- A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Galderma R&DNCT04562116Written as Nemolizumab
- A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo NodularisCompletedPhase 3Galderma R&DNCT05052983Written as Nemolizumab
- Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Galderma R&DNCT03985943Written as Nemolizumab
- Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Galderma R&DNCT03989349Written as Nemolizumab
- Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)CompletedPhase 3Galderma R&DNCT04501666Written as Nemolizumab 30 mg
Codes
What other systems call nemolizumab · ClinicalTrials.gg INT000569
- MeSH (NLM) C000612881nemolizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) GN465U8B72NEMOLIZUMABConfirmed FDA, NLM
- NCI Thesaurus C170211NemolizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000612881 | nemolizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | GN465U8B72 | NEMOLIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C170211 | Nemolizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.